UK is set to launch the first human trials of ground-breaking drug shown to repair DNA damage that contributes to Alzheimer's disease, reported sources.
The study, also being launched this week in hospitals in France and Spain, will see the neuro-degenerative condition treated with an agent which acts as a DNA repair kit to restore memory and reverse behavioural changes such as aggression and social avoidance, the express.co.uk reported late on Sunday.
Alzheimers Disease
Alzheimer''s disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.
Advertisement
‘Alzheimer’s drug human trial: The 26-week human trial, which will include 90 patients with mild to moderate Alzheimer's, could potentially lead to a "cure" for the disease affecting nearly 50 million people worldwide.’
Tweet it Now
The drug, known as ORY-2001, contains a small molecule which inhibits two enzymes in the brain, LSD1, and MAOB, which are responsible for promoting DNA damage and inhibiting repair.
By blocking their action, the new drug repairs and prevents further damage.
The drug also stops inflammation in the brain, a key factor perhaps causing mental decline, the report said.
![Quiz On Alzheimer’s Disease]( "Quiz On Alzheimer’s Disease")
Alzheimer's disease (AD) is the most common form of dementia. Participate in this quiz to find out how much you know about this debilitating disease.
"Curing Alzheimer's is now on the horizon. The mechanism of this drug may lead to treatments that protect genetic material from the influences of ageing," Stuart Ratcliffe, chief scientific officer at St Pancras Clinical Research in London, was quoted as saying.
"I believe this is ground-breaking. Neuro-degenerative diseases are a massive problem so heading these off is a holy grail of medicine," Ratcliffe added.
Tests on mice have shown that one treatment a day can reverse the disease, giving new hope that a cure is on the horizon.
"Alzheimer's is our biggest killer and is spiralling," Ratcliffe said.
"It is therefore paramount that new treatments are discovered and developed, otherwise the societal and health care costs of Alzheimer's alone could bankrupt us," he added.
Source: IANS
The drug also stops inflammation in the brain, a key factor perhaps causing mental decline, the report said.
Quiz On Alzheimer’s Disease
Alzheimer's disease (AD) is the most common form of dementia. Participate in this quiz to find out how much you know about this debilitating disease.
Advertisement
"Curing Alzheimer's is now on the horizon. The mechanism of this drug may lead to treatments that protect genetic material from the influences of ageing," Stuart Ratcliffe, chief scientific officer at St Pancras Clinical Research in London, was quoted as saying.
"I believe this is ground-breaking. Neuro-degenerative diseases are a massive problem so heading these off is a holy grail of medicine," Ratcliffe added.
Tests on mice have shown that one treatment a day can reverse the disease, giving new hope that a cure is on the horizon.
"Alzheimer's is our biggest killer and is spiralling," Ratcliffe said.
"It is therefore paramount that new treatments are discovered and developed, otherwise the societal and health care costs of Alzheimer's alone could bankrupt us," he added.
Source: IANS
Caring for Alzheimers disease patients
Alzheimer's disease is a complex brain disorder that triggers the most common form of dementia. The slide show will show how patients need support and care as dementia progresses.
Advertisement
 First Alzheimer’s Drug to Slow Disease Progression Gets FDA ApprovalThe FDA-approved drug for Alzheimer's disease, Leqembi, is poised to provide significant benefits to early-stage patients by reducing the disease's progression. | Advertisement
|
Advertisement
Recommended Readings
Latest Clinical Trials News
FDA approval is sought for “artificial womb” clinical trials (mimicking lamb trials) in humans, that can potentially reduce mortality in premature babies.
Increasing the levels of platelet-derived factors in the body may lessen the effect of age-related degenerative changes and cognitive impairment in the brain.
Constructing bacteria to become drug resistant only when they took up DNA containing cancer-associated changes, could be useful in detecting cancer.
Eli Lilly's Mounjaro may prove an alternative to bariatric surgery, stated clinical trial results.
After achieving an 80 percent success rate in treating animals, Indian doctors plan to advance to human trials for the liquid cornea.
